BNP Paribas Asset Management
AMLX icon

BNP Paribas Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

BNP Paribas Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.7K Buy
1,418
+103
+8% +$1.45K ﹤0.01% 2038
2025
Q4 		$16K Buy
+1,315
New +$17.9K ﹤0.01% 2008

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BNP Paribas Asset Management's AMLX Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Amylyx Pharmaceuticals (AMLX) stake by 7.8% in Q1 2026, buying an estimated $1.45K and bringing the position to 1,418 shares worth $19.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2038.

BNP Paribas Asset Management first reported a position in AMLX in Q4 2025 and has held it in 2 quarters since. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • BNP Paribas Asset Management held 1,418 shares of Amylyx Pharmaceuticals worth $19.7K as of Q1 2026.
  • BNP Paribas Asset Management bought 103 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $1.45K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #2038 holding.
  • BNP Paribas Asset Management first reported a position in Amylyx Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.